Theralink(R) Technologies Appoints Michael Fanelli
Post# of 110
(Total Views: 480)
Posted On: 07/23/2020 11:16:23 PM
Theralink(R) Technologies Appoints Michael Fanelli Senior Director, Biopharma Commercial Operations
Mr. Fanelli joins the Theralink® team having previously held positions at Metabolon Inc., Core Diagnostics, Nanostring Technologies and Bio-Rad Laboratories
DENVER, CO / ACCESSWIRE / July 22, 2020 / OncBioMune d/b/a Theralink Technologies (OTC:OBMP), a molecular profiling company specializing in biomarker assay services that target multiple areas of oncology, announced today the appointment of Mr. Michael Fanelli as Senior Director of Biopharma Commerial Operations.
Prior to joining Theralink®, Mr. Fanelli was Business Development Executive, Strategic Accounts for Metabolon Inc. where he was responsible for establishing mutually beneficial partnership agreements for the Metabolon services and diagnostics development portfolio. Prior to that Mr. Fanelli was Director of Business Development at Core Diagnostics, Inc. where he led the development of new clients and sales of the Core Diagnostics pre-clinical and clinical services in the oncology space. Prior to that from 2012 to 2018, Mr. Fanelli was Director Life Science Sales - US West at Nanostring Technologies and Northwest Regional Manager at Bio-Rad Laboratories. Mr. Fanelli has a Master of Science, Biology (Molecular) from California State University San Marcos and Bachelor of Science in Biology (Cellular and Molecular) from California State University Humboldt.
"Michael is an important addition to our team as we prepare for the commercialization of our patented proteomic technology," said Mick Ruxin, M.D. President and CEO of Theralink Technologies, Inc. "Michael brings to our team extensive experience and deep relationships in our industry that will assist us in accelerating the sales cycle. We want to welcome Michael to our team and look forward to working closely with him on our business development and sales strategy."
"Theralink's technology is solving a significant challenge in translational and clinical oncology by providing access to more predictive proteomics biomarkers. Leveraging my experience in commercial leadership and business development, I look forward to immediately implementing an effective commercialization strategy with the Theralink team," stated Michael Fanelli, newly appointed Senior Director of Biopharma Commercial Operations.
Read More: https://investorshangout.com/recentnews/OBMP#ixzz6T4vnqdgN
Mr. Fanelli joins the Theralink® team having previously held positions at Metabolon Inc., Core Diagnostics, Nanostring Technologies and Bio-Rad Laboratories
DENVER, CO / ACCESSWIRE / July 22, 2020 / OncBioMune d/b/a Theralink Technologies (OTC:OBMP), a molecular profiling company specializing in biomarker assay services that target multiple areas of oncology, announced today the appointment of Mr. Michael Fanelli as Senior Director of Biopharma Commerial Operations.
Prior to joining Theralink®, Mr. Fanelli was Business Development Executive, Strategic Accounts for Metabolon Inc. where he was responsible for establishing mutually beneficial partnership agreements for the Metabolon services and diagnostics development portfolio. Prior to that Mr. Fanelli was Director of Business Development at Core Diagnostics, Inc. where he led the development of new clients and sales of the Core Diagnostics pre-clinical and clinical services in the oncology space. Prior to that from 2012 to 2018, Mr. Fanelli was Director Life Science Sales - US West at Nanostring Technologies and Northwest Regional Manager at Bio-Rad Laboratories. Mr. Fanelli has a Master of Science, Biology (Molecular) from California State University San Marcos and Bachelor of Science in Biology (Cellular and Molecular) from California State University Humboldt.
"Michael is an important addition to our team as we prepare for the commercialization of our patented proteomic technology," said Mick Ruxin, M.D. President and CEO of Theralink Technologies, Inc. "Michael brings to our team extensive experience and deep relationships in our industry that will assist us in accelerating the sales cycle. We want to welcome Michael to our team and look forward to working closely with him on our business development and sales strategy."
"Theralink's technology is solving a significant challenge in translational and clinical oncology by providing access to more predictive proteomics biomarkers. Leveraging my experience in commercial leadership and business development, I look forward to immediately implementing an effective commercialization strategy with the Theralink team," stated Michael Fanelli, newly appointed Senior Director of Biopharma Commercial Operations.
Read More: https://investorshangout.com/recentnews/OBMP#ixzz6T4vnqdgN
(0)
(0)Theratechnologies Inc. (THER) Stock Research Links
Scroll down for more posts ▼